Electrocardiographic Left Ventricular Hypertrophy and Risk of Coronary Heart Disease
The Framingham Study
- WILLIAM B. KANNEL, M.D., F.A.C.P., M.P.H.;
- TAVIA GORDON;
- WILLIAM P. CASTELLI, M.D.; and
- JAMES R. MARGOLIS, M.D.
Abstract
Risk of clinically overt coronary heart disease in 190 persons with "definite" and 264 with "possible" electrocardiographic left ventricular hypertrophy (ECG-LVH) was compared with that of a total cohort of 5,127 men and women followed over 14 years. Prevalence of both coronary heart disease and ECG-LVH increased in proportion to antecedent blood pressure. Persons who acquired "definite" ECG-LVH had a residual threefold increased risk of clinically overt coronary heart disease after adjustment for the effect of coexisting hypertension. "Possible" ECG-LVH was associated with a twofold increased risk, but this was virtually obliterated on adjustment for hypertension. Risk of every clinical manifestation of coronary heart disease, and of death in particular, was increased, and 40% with prior ECG-LVH died in their initial attack, a fatality rate comparable with that of persons with prior overt coronary heart disease. ECG-LVH is thus a grave prognostic sign and a harbinger of clinically overt coronary heart disease. It is tempting to hypothesize that ECG-LVH without other explanation based mainly on increased voltage (possible LVH) is largely an expression of hypertensive hypertrophy and that with more marked voltage increases accompanied by S-T and T wave abnormality (definite LVH) indicates ischemic myocardial involvement.
Article and Author Information
-
▸From the Heart Disease Epidemiology Study, Framingham, Mass.; and the National Heart Institute, National Institutes of Health, Bethesda, Md.
-
▸Requests for reprints should be addressed to William B. Kannel, M.D., Public Health Service, Department of Health, Education and Welfare, 25 Evergreen St., Framingham, Mass. 01701
RSS Feeds









